autarkize | $2,502,492 | (Nov 1, 2024)
Keel | $5,933,454 | (Nov 1, 2024)
Decart | $21,000,000 | (Nov 1, 2024)
Ataraxis AI
United States
- New York, NY
- 01/11/2024
- Seed
- $4,000,000
Ataraxis is an AI precision medicine company transforming cancer diagnostics and patient outcomes through the power of AI. We are addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data.
Our first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive test for breast cancer and provides greater accuracy than standard of care genomic assays. To learn more, visit ataraxis.ai.
- Industry Biotechnology
- Website https://www.ataraxis.ai/
- LinkedIn https://www.linkedin.com/company/ataraxis-ai/
Related People
Jan Witowski MD PhDFounder
United States -
New York, New York
CEO and co-founder of Ataraxis AI. Physician-scientist. Previously postdoc at NYU Langone Health, Harvard Medical School & Mass General. 10 years of experience in medical image processing, with focus on artificial intelligence, cancer imaging, and developing clinical diagnostic tools.
OpenOrigins | $4,500,000 | (Nov 1, 2024)
MOTORMIA | $8,000,000 | (Nov 1, 2024)
MealMe, Inc. | $8,000,000 | (Nov 1, 2024)
Definition Health | $7,412,756 | (Nov 1, 2024)
LINGO | $2,250,000 | (Nov 1, 2024)
ContraForce | $3,250,000 | (Nov 1, 2024)
hotglue | $4,000,000 | (Oct 31, 2024)
Third Wave Automation | $27,000,000 | (Oct 31, 2024)